Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

SourceStock Titan
Date Published06/15/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Ocugen, Inc.
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Domestically, the work will be done:Outsourced
City reshored to:Malvern
State(s) reshored to:PA
If relevant, work nearshored to:-
Industry(ies):Chemicals, biopharmaceutical
Product(s) reshoredbiopharmaceuticals, COVAXIN™, COVID-19 vaccine
What domestic positive factors made reshoring more attractive?Impact on domestic economy, Skilled workforce availability/training, Other, import replacement, Covid-19
Find Reshoring Articles